Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.411 USD | -4.42% | -11.27% | -36.77% |
May. 13 | Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
Business Summary
Number of employees: 2
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 19-09-09 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 20-07-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19-07-18 |
Paul Lammers
BRD | Director/Board Member | 66 | 19-07-18 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 20-06-18 |
William McVicar
CHM | Chairman | 66 | 19-07-18 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Tess Burleson
BRD | Director/Board Member | 57 | 19-07-18 |
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,776,433 | 4,486,213 ( 93.92 %) | 0 | 93.92 % |
Company contact information
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.77% | 1.96M | |
+51.85% | 57.87B | |
+41.05% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- SLRX Stock
- Company Salarius Pharmaceuticals, Inc.